The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...

Other institutions, including Mariner and Ameritas Investment Partners, also increased exposure to the stock. ・Sellas said on Tuesday that its Phase 3 Regal AML study had reached 78 events as of May ...

Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy ...

Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...

Investors are watching three upcoming Sellas healthcare and cancer conferences this month. ・Sellas’ Phase 3 Regal AML study is now just two events away from final analysis and topline data. ・Sellas ...

COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the ...

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat ...